Kai Habben

644 total citations
13 papers, 536 citations indexed

About

Kai Habben is a scholar working on Molecular Biology, Biochemistry and Oncology. According to data from OpenAlex, Kai Habben has authored 13 papers receiving a total of 536 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Biochemistry and 4 papers in Oncology. Recurrent topics in Kai Habben's work include Lipid metabolism and biosynthesis (5 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Kai Habben is often cited by papers focused on Lipid metabolism and biosynthesis (5 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Kai Habben collaborates with scholars based in Germany, United Kingdom and United States. Kai Habben's co-authors include Mark Kockx, Sabine Eckhardt, Joseph Eid, Stephen Leong, Gérard Greig, Thorsten Gutjahr, Amita Patnaik, Terri Warren, Joseph Aisner and Marc J. van de Vijver and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Kai Habben

13 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kai Habben Germany	9	285	230	152	130	121	13	536
Karen A. Reeves United States	8	437 1.5×	318 1.4×	166 1.1×	166 1.3×	197 1.6×	11	754
Greg Friberg United States	10	259 0.9×	189 0.8×	116 0.8×	108 0.8×	95 0.8×	15	488
Alicia Morresi‐Hauf Germany	16	214 0.8×	266 1.2×	233 1.5×	125 1.0×	113 0.9×	42	792
Susan Koujak United States	8	741 2.6×	254 1.1×	168 1.1×	123 0.9×	277 2.3×	10	991
Tetsukan Woo Japan	19	378 1.3×	355 1.5×	374 2.5×	62 0.5×	223 1.8×	42	880
Jung Hun Song South Korea	10	384 1.3×	285 1.2×	117 0.8×	321 2.5×	92 0.8×	10	757
Michio Kosugi Japan	15	427 1.5×	175 0.8×	178 1.2×	100 0.8×	136 1.1×	27	787
Dongfeng Niu China	13	306 1.1×	166 0.7×	117 0.8×	124 1.0×	83 0.7×	29	601
Tamara Aleksic United Kingdom	15	454 1.6×	245 1.1×	98 0.6×	258 2.0×	219 1.8×	18	786
Rana Sullivan United States	10	349 1.2×	259 1.1×	323 2.1×	66 0.5×	86 0.7×	19	643

Countries citing papers authored by Kai Habben

Since Specialization

Citations

This map shows the geographic impact of Kai Habben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Habben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Habben more than expected).

Fields of papers citing papers by Kai Habben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Habben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Habben. The network helps show where Kai Habben may publish in the future.

Co-authorship network of co-authors of Kai Habben

This figure shows the co-authorship network connecting the top 25 collaborators of Kai Habben. A scholar is included among the top collaborators of Kai Habben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Habben. Kai Habben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Wang, Ka, Tilman Schlothauer, Angelika Lahr, et al.. (2017). An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism. Cancer Chemotherapy and Pharmacology. 79(4). 661–671. 8 indexed citations

Lassen, Ulrik, Olivier Chinot, Catherine McBain, et al.. (2015). Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncology. 17(7). 1007–1015. 32 indexed citations

Lassen, Ulrik, Olivier Chinot, Catherine McBain, et al.. (2013). Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 31(15_suppl). 2092–2092. 3 indexed citations

Habben, Kai, Paul Delmar, Carrie Brownstein, et al.. (2011). Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). 7584–7584. 8 indexed citations

Drury, Suzanne, Simone Detre, Alexandra Léary, et al.. (2011). Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocrine Related Cancer. 18(5). 565–577. 67 indexed citations

Ramalingam, Suresh S., David R. Spigel, David Chen, et al.. (2011). Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(34). 4574–4580. 115 indexed citations

Kurzrock, Razelle, Amita Patnaik, Joseph Aisner, et al.. (2010). A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(8). 2458–2465. 158 indexed citations

Dowsett, Mitch, Wedad Hanna, Mark Kockx, et al.. (2007). Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathology. 20(5). 584–591. 103 indexed citations

Kerkhoff, Claus, et al.. (2000). Solubilization, partial purification and photolabeling of the integral membrane protein lysophospholipid:acyl‐CoA acyltransferase (LAT). European Journal of Biochemistry. 267(21). 6339–6345. 8 indexed citations

10.

Kerkhoff, Claus, et al.. (1998). Substrate Specificity of Acyl-CoA:Lysophospholipid Acyltransferase (LAT) from Pig Spleen. Archives of Biochemistry and Biophysics. 351(2). 220–226. 7 indexed citations

11.

Haase, Dirk, et al.. (1998). Synthesis of an unsaturated fatty acid analogue (18-(4′-azido-2′-hydroxybenzoylamino)-oleic acid) and its interaction with lysophosphatidylcholine: acyl-CoA-O-acyltransferase. Journal of Lipid Research. 39(5). 1118–1126. 6 indexed citations

12.

Kerkhoff, Claus, et al.. (1997). The Mitogen-Induced Lysophospholipid:acyl-CoA Acyltransferase (LAT) Expression in Human T-Lymphocytes Is Diminished by Hydrocortisone. Biochemical and Biophysical Research Communications. 237(3). 632–638. 10 indexed citations

13.

Kerkhoff, Claus, et al.. (1996). Identification of two different lysophosphatidylcholine:acyl-CoA acyltransferases (LAT) in pig spleen with putative distinct topological localization. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1302(3). 249–256. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact